Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance mechanisms...
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK~+) lung cancers; yet the durability of response is limited by drug resistance. Elucidation of on-target resistance ...
FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). [Press release]. https://www.businesswire.com/news/home/20241218355621/en/FDA-Approval-of-Ensartinib-for-ALK-Positive-Locally-Advanced-or-Metastatic-Non-Small-Cell-Lung-Cancer-NSCLC...
Crizotinib, an orally bioavailable inhibitor of ALK, provides significant benefit for patients with ALK-positive (ALK+) NSCLC in association with characteristic, mostly mild, toxic effects, and this drug has been approved by the FDA for clinical use in this molecularly defined subgroup of lung ...
Pharmacogenomics and Personalized Medicine Dovepress open access to scientific and medical research Open Access Full Text Article Review ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients This article was published in the following Dove Press journal: Pharmacogenomics ...
ALK-positiveLungCancer KengoTakeuchi, 1 YoungLimChoi, 3 YukiTogashi, 1 ManabuSoda, 3 SatokoHatano, 1 KentaroInamura, 1 ShujiTakada, 3 ToshihideUeno, 3 YoshihiroYamashita, 3 YukitoshiSatoh, 2 SakaeOkumura, 2 KenNakagawa, 2 YuichiIshikawa, ...
All ALK-positive and ALK-negative controls had advanced NSCLC. ALK-positive patients treated with crizotinib had a one-year overall survival rate of 74% and a two-year overall survival rate of 54%. Median overall survival had not been reached. This compared with outcomes for the ALK...
Pharmacogenomics and Personalized Medicine Dovepress open access to scientific and medical research Open Access Full Text Article Review ALK (D5F3) CDx: an immunohistochemistry assay to identify ALK-positive NSCLC patients This article was published in the following Dove Press journal: Pharmacogenomics ...
Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.In the final episode of this 3-part Oncology Unplugged series, Ch...
ALK-positive advanced non-small cell lung cancer 青云英语翻译 请在下面的文本框内输入文字,然后点击开始翻译按钮进行翻译,如果您看不到结果,请重新翻译! 翻译结果1翻译结果2翻译结果3翻译结果4翻译结果5 翻译结果1复制译文编辑译文朗读译文返回顶部 正在翻译,请等待......